CRNX vs. AVDL, AKRO, BCYC, IONS, ROIV, TMDX, IDYA, AMED, SHC, and APGE
Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO), Bicycle Therapeutics (BCYC), Ionis Pharmaceuticals (IONS), Roivant Sciences (ROIV), TransMedics Group (TMDX), IDEAYA Biosciences (IDYA), Amedisys (AMED), Sotera Health (SHC), and Apogee Therapeutics (APGE). These companies are all part of the "medical" sector.
Avadel Pharmaceuticals (NASDAQ:AVDL) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
Avadel Pharmaceuticals received 192 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 66.18% of users gave Crinetics Pharmaceuticals an outperform vote while only 65.01% of users gave Avadel Pharmaceuticals an outperform vote.
69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 4.0% of Avadel Pharmaceuticals shares are owned by company insiders. Comparatively, 7.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Avadel Pharmaceuticals has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -4,223.27%. Avadel Pharmaceuticals' return on equity of -52.93% beat Crinetics Pharmaceuticals' return on equity.
Avadel Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avadel Pharmaceuticals and Avadel Pharmaceuticals both had 5 articles in the media. Crinetics Pharmaceuticals' average media sentiment score of 0.76 beat Avadel Pharmaceuticals' score of 0.60 indicating that Avadel Pharmaceuticals is being referred to more favorably in the media.
Avadel Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Avadel Pharmaceuticals currently has a consensus price target of $22.57, suggesting a potential upside of 24.77%. Crinetics Pharmaceuticals has a consensus price target of $54.17, suggesting a potential upside of 22.49%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Avadel Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.
Summary
Avadel Pharmaceuticals beats Crinetics Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Crinetics Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crinetics Pharmaceuticals Competitors List
Related Companies and Tools
